

CODING AND BILLING SHEET

Immune Globulin Code

CPT^{®a} code **90380** or **90381** should be assigned on all claims for Beyfortus. These codes describe a 0.5-mL dose and a 1-mL dose of this pediatric, once per season, RSV^b immunization. It is not necessary to use modifier-51 when reporting these codes with another procedure. See the grid below for more information on billing these codes.

CPT Code	Code Description	Suggested Use						
	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	Bill 1 unit of 90380 when a 0.5-mL dose is provided.						
00701	Respiratory syncytial virus, monoclonal antibody,	Bill 1 unit of 90381 when a 1-mL dose is provided.						
90381	seasonal dose; 1 mL dosage, for intramuscular use	Bill 2 units of 90381 when a 2-mL dose is provided.						
Source: 2023 Current Procedural Terminology - all code descriptions are as defined by the American Medical Association.								

National Drug Codes (NDCs)

Some payers require an NDC in addition to the CPT code for the product. In such cases, it is important to format the NDC correctly or the claim will be denied and you will need to resubmit a corrected claim in order to be reconsidered for payment. Begin by determining if the payer requires the carton NDC or the unit-of-use NDC. On line 24A, place qualifier N4, the 11-digit NDC number (without hyphens), the Unit-of-Measure, and Units Dispensed. To convert the Beyfortus NDC to the required 11-digit format, add a leading zero in the middle section of numbers (ex. 49281-575-00 = 49281-0575-00). Unit-of-Measure, ML, is reported when the product is supplied in a liquid format. Units Dispensed is the actual decimal quantity administered. Continue to bill CPT code 90380 or 90381 and administration code 96372. Below is how to submit the NDCs for Beyfortus.

When the Payer Requires Carton NDC	When the Payer Requires Unit-of-Use NDC	Description				
N449281057515 ML0.5	N449281057500 ML0.5	Carton of 5, 0.5-mL prefilled syringes (5x1)				
N449281057415 ML1.0	N449281057488 ML1.0	Carton of 5, 1-mL prefilled syringes (5x1)				
N449281057415 ML2.0	N449281057488 ML2.0	Carton of 5, 1-mL prefilled syringes (5x1)				

Administration Code

The administration of an immune globulin is reported in addition to the immune globulin product code (ie, assign the code for the product along with the appropriate code for its administration). To appropriately code for administration of an immune globulin administered by intramuscular injection, use CPT code 96372. See the grid below for more information on billing this code.

Code	Code Description	Suggested Use							
	Therapeutic, prophylactic, or diagnostic injection	Bill 1 unit of 96372 when a 0.5-mL dose is administered.							
96372	(specify substance or drug); subcutaneous or	Bill 1 unit of 96372 when a 1-mL dose is administered.							
	intramuscular	Bill 2 units of 96372 when two 1-mL doses are administered.							
Source:	Source: 2023 Current Procedural Terminology - all code descriptions are as defined by the American Medical Association.								

Beyfortus is **indicated** for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

- · Neonates and infants born during or entering their first RSV season.
- · Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

IMPORTANT SAFETY INFORMATION Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Please see additional Important Safety Information continued on page 2.



Diagnosis Code (ICD-10-CM)d

Below are the suggested diagnosis codes that may be appropriate when submitting claims for Beyfortus and its administration. The ICD-10 code should be linked to both the Beyfortus code 90380 or 90381, and its administration code 96372. Assign the appropriate code based on review of the documentation in the medical record.


ICD-10-CM Code	Code Description	Suggested Use						
Z23	Encounter for immunization	When a 0.5-mL dose or 1-mL dose of RSV is administered as a prophylactic immunization.						
Z29. 11	Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV)	When a 2-mL dose of RSV is administered as a prophylactic immunization due to a high risk condition.						
Applicable High- Risk Condition	Applicable High-Risk Condition Code Description	When a 2-mL dose of RSV is administered as a prophylactic immunization due to a high risk condition, add Z29.11 and the applicable ICD-10 code that describes each patient's high-risk condition.						

Billing for Visits and an Immunization

If an immunization is the only service provided, a visit is not billed. When a separate and significant visit is provided along with an immunization, bill for the visit and the immunization services. When an immunization is administered at any type of visit, the modifier -25 may need to be attached to the evaluation and management code along with an ICD-10 which describes the reason for the visit to identify that it is separate and significantly different than other services billed. Check with your payers to confirm their requirements regarding the use of the -25 modifier.

Billing Examples

An infant is seen for a well visit and receives a 0.5-mL dose of Beyfortus. The physician counsels the parent on the immunization. The patient's plan requires NDCs on claims.



Do you have questions on coverage or payment for Sanofi products? Contact a Sanofi Reimbursement Specialist (RS). Call 1-800-VACCINE (1-800-822-2463) and choose the prompt for the RS.

Visit <u>www.crackingthecodestraining.com</u> for on-demand coding and billing videos and resources for Sanofi products.

Visit the Coding Education and Reimbursement Support Page on <u>VaccineShop.com</u>® for additional coding resources for Sanofi products.

IMPORTANT SAFETY INFORMATION [CONTINUED] Warnings and Precautions

• **Hypersensitivity Including Anaphylaxis:** Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.

Please see additional Important Safety Information continued on page 3.



Billing Examples continued

An infant is seen for a well visit and receives a 1-mL dose of Beyfortus. The nurse practitioner counsels the parent on the immunization. The patient's plan requires NDCs on claims.

, IZ00.129 visit must describe the reason for the visit and							
5	F	G DAYS F	H I PSDT	J	K Z		
CODE	¢ CHARGES	OR F	amily	сов	RESERVED FOR LOCAL USE		
1		1			<u>≥</u>		
2		1	Bill 1 unit of CPT code 96372 for administering a 1-mL dose of Beyfortus. Link to the diagnosis code for the immunization Z23.				
2		1					
١	visit and code.	visit and code. 23. PBV of Beyford	visit and code. 23. PBV of Beyfortument DAYS	visit and code. 23. PPI of Beyfortus and li the im F G HARGES OR ON Family Plan EMG 1 1 Bill 2 1 For act Beyfortus and line of B	of Beyfortus and link to the immules of Beyfortu		

A child is seen for an evaluation and management visit and receives a 2-mL dose of Beyfortus. The registered nurse counsels the parent on the immunization. The patient's plan requires NDCs on claims.

The ICD-10 code attached to the office visit must describe the reason for the visit. Modifier -25 is attached to the visit to show it is separate and significant from the immunization services.							Bill 2 units of CPT code 90381 for a 2-mL dose of Beyfortus and link to the diagnosis code for the immunization Z29.11 and the diagnosis code which describes the patient's high risk condition.						the diagnosis code for and the diagnosis code	
24. A N449281057415 DATE(S) OF SERVIC From MM DD YY MM	E _{To}	B Place of Service	of	PROCEDURES, SERVI (Explain Unusual (CPT/HCPCS M		DIAGNOSIS CODE	\$ CHARG	GES	DAYS OR UNITS	Family	EMG	сов	RESERVED FOR LOCAL USE	
10 10 23 10	10 23	11		99203 25		1			1	Bill 2 units of 96372 for				
2 10 10 23 10	10 23	11		90381		1,2			2		administering two 1-mL doses of Beyfortus. Link to the diagnosis			
3 10 10 23 10	10 23	11		96372		1,2			2	code Z29.11 and the diagnosis code which describes the patient's high				
1			_					1	1	VV	HICI	rue	risk condition.	

Vaccines for Children (VFC) Billing

Be aware that many Medicaid plans stipulate which codes can be billed for administering immunizations available through the VFC program. Be sure to investigate the coding rules for your Medicaid plans, for this immune globulin immunization, in case the required coding is different than the coding explained here.

CVX and MVX Codes

CVX and MVX codes are used to populate immunization registries. The CVX code indicates which product was used and the MVX code indicates the manufacturer of the product. When a MVX (manufacturer) code is paired with a CVX (product administered) code, the specific trade named product can be identified. The CVX codes for Beyfortus are **306** for a 0.5-mL dose and **307** for a 1-mL dose. The MVX for Sanofi is **PMC**^c.

IMPORTANT SAFETY INFORMATION [CONTINUED] Warnings and Precautions

• Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see Prescribing Information for Beyfortus.

^a CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association; ^b RSV = Respiratory syncytial virus; ^c PMC = Pasteur Merieux Connaught; ^d ICD-10 = International Classification of Diseases, 10th Revision.

The information contained in this Coding and Billing Sheet is provided for informational purposes only. Every reasonable effort has been made to verify the accuracy of the information; however, this quick reference is not intended to provide specific guidance on how to utilize, code, bill, or charge for any product or service. Health care providers should make the ultimate decision as to when to use a specific product based on clinical appropriateness for a particular patient. Third-party payment for medical products and services is affected by numerous factors and Sanofi Inc. cannot guarantee success in obtaining insurance payments.

